# US 11,028,444 B2 · Survival predictor for diffuse large B cell lymphoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,028,444 B2
- Document ID: US11028444B2
- Status: Granted
- Kind: B2
- Application number: 15/965,510
- Filed: 2018-04-27
- Published: 2018-08-30
- Granted: 2021-06-08
- Earliest claimed: 2008-06-06
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services; Arizona Board of Regents on Behalf of the University of Arizona; Queen Mary University of London; Board of Regents of the University of Nebraska; Oslo University Hospital HF; Oregon Health & Science University; University of Rochester; Hospital Clinic De Barcelona; Universitat De Barcelona; British Columbia Cancer Agency Branch; Julius-Maximilians-University of Würzburg
- Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Services; Arizona Board of Regents on Behalf of the University of Arizona; Queen Mary University of London; Board of Regents of the University of Nebraska; Oslo University Hospital HF; Oregon Health & Science University; University of Rochester; Hospital Clinic de Barcelona; Universitat de Barcelona; British Columbia Cancer Agency Branch; Julius-Maximilians-University of Würzburg
- Inventors: Lisa M. Rimsza; Andrew T. Lister; Wing C. Chan; Dennis Weisenburger; Jan Delabie; Erlend B. Smeland; Harald Holte; Stein Kvaløy; Rita M. Braziel; Richard I. Fisher; Pedro Jares; Armando Lopez-Guillermo; Elias Campo Guerri; Elaine S. Jaffe; Georg Lenz; Wyndham H. Wilson; George W. Wright; Sandeep S. Dave; Louis M. Staudt; Randy D. Gascoyne; Joseph M. Connors; Hans-Konrad Muller-Hermelink; Andreas Rosenwald; German Ott
- Web page: https://patentgrep.com/patent/US11028444B2

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 35/00: Antineoplastic agents
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

## Claims

### Claim 1

A method of treating a subject for diffuse large B cell lymphoma (DLBCL) which method comprises:
i) evaluating the subject for antiangiogenic therapy of DLBCL, comprising:
a) isolating gene expression product from one or more DLBCL biopsy samples from the subject;
b) obtaining a gene expression profile from the gene expression product by detecting an expression level for VWF, CD31 (PECAM1), EGFL7, MMRN2, GPR116, and SPARCL, KDR (VEGF receptor-2), Grb10, integrin alpha 9, TEK, ROBO4, ERG, CAV1, CAV2, and EHD2;
c) determining the subject's signature value from the gene expression profile; and
d) determining whether the subject's signature value is higher or lower than a standard value, wherein antiangiogenic therapy is indicated by a signature value that is higher than the standard value and antiangiogenic therapy is not indicated by a signature value that is not higher than the standard value,
ii) determining that the subject's signature value is higher than the standard value, and
iii) treating the subject with antiangiogenic therapy.

### Claim 2 (depends on 1)

The method of claim 1, wherein the signature value corresponds to the average of the expression levels of the genes in the gene expression profile.

### Claim 3 (depends on 1)

The method of claim 1, wherein obtaining a gene expression profile from the gene expression product comprises detecting an expression level for NM_014601, NM_017789, NM_000484, NM_004684, NM_002291, NM_000210, NM_000552, NM_001233, NM_006404, NM_000609, NM_002253, NM_001442, NM_016315, NM_006307, NM_000163, NM_000950, NM_002666, NM_000459, NM_004797, NM_000442, NM_198098, NM_021005, NM_014220, NM_001001549, NM_006108, NM_001003679, NM_000599, NM_001753, NM_005841, NM_015345, NM_015234, NM_006108, NM_016215, NM_022481, XM_371262, NM_016563, NM_006094, NM_019035, NM_019055, NM_002207, XM_930608, XM_037493, NM_052954, NM_002837, NM_019558, NM_001442, NM_024756, BQ897248, NM_020663, AK091419, NM_015719, NM_012072, NM_000300, NM_019105, NM_030754, NM_019105, NM_014220, NM_000668, NM_001354, NM_001032281, NM_001001924, NM_019105, NM_004449, NM_018407, NM_000331, NM_019105, NM_001034954, NM_017734, NM_024756, NM_006744, and NM_001034954.

### Claim 4 (depends on 3)

The method of claim 3, wherein the signature value corresponds to the average of the expression levels of the genes in the gene expression profile.